Market revenue in 2023 | USD 599.4 million |
Market revenue in 2030 | USD 946.9 million |
Growth rate | 6.8% (CAGR from 2023 to 2030) |
Largest segment | Inhaled |
Fastest growing segment | Other Allergens |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inhaled, Drug, Other Allergens, Food |
Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Inhaled was the largest segment with a revenue share of 55.12% in 2023. Horizon Databook has segmented the Brazil allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
The allergy diagnostics and therapeutics market is projected to showcase a lucrative growth rate over the forecast period due to rising incidence of allergies due to increasing pollution, rapid changes in the environment, and growing adoption of sedentary lifestyle.
The adoption of various strategic initiatives by key players in the region further boosts market growth. Advancements in IVD technologies, increasing number of clinical trials, and launches also positively impact the market. Various government initiatives to improve healthcare infrastructure further fuel market growth.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account